Table 1 Characteristics of the patients with COVID-19
From: Azvudine efficacy in reducing mortality in COVID-19 patients
Variables | Total (n = 2862) | Control group (n = 1372) | Azvudine group (n = 1490) | P |
|---|---|---|---|---|
29-day survival, n (%) | ||||
Survival | 2715 (94.9) | 1302 (94.9) | 1413 (94.8) | 0.937 |
All-cause death | 147 (5.1) | 70 (5.1) | 77 (5.2) | |
Hospital days | 10.47 ± 6.43 | 9.03 ± 6.70 | 11.79 ± 5.87 | < 0.001 |
Gender, n (%) | ||||
Men | 1654 (57.8) | 715 (52.1) | 939 (63) | < 0.001 |
Women | 1208 (42.2) | 657 (47.9) | 551 (37) | |
Age | 65.19 ± 16.99 | 61.71 ± 18.49 | 68.41 ± 14.78 | < 0.001 |
BMI | 23.17 ± 3.99 | 23.03 ± 4.15 | 23.32 ± 3.83 | 0.137 |
Cardiovascular diseases, n (%) | ||||
No | 2512 (87.8) | 1219 (88.8) | 1293 (86.8) | 0.091 |
Yes | 350 (12.2) | 153 (11.2) | 197 (13.2) | |
Hypertension, n (%) | ||||
No | 1636 (57.2) | 843 (61.4) | 793 (53.2) | < 0.001 |
Yes | 1226 (42.8) | 529 (38.6) | 697 (46.8) | |
Diabetes mellitus, n (%) | ||||
No | 2269 (79.3) | 1138 (82.9) | 1131 (75.9) | < 0.001 |
Yes | 593 (20.7) | 234 (17.1) | 359 (24.1) | |
Chronic kidney disease, n (%) | ||||
No | 2538 (88.7) | 1232 (89.8) | 1306 (87.7) | 0.070 |
Yes | 324 (11.3) | 140 (10.2) | 184 (12.3) | |
Chronic obstructive pulmonary disease, n (%) | ||||
No | 2499 (87.3) | 1216 (88.6) | 1283 (86.1) | 0.043 |
Yes | 363 (12.7) | 156 (11.4) | 207 (13.9) | |
Cancer, n (%) | ||||
No | 2477 (86.5) | 1137 (82.9) | 1340 (89.9) | < 0.001 |
Yes | 385 (13.5) | 235 (17.1) | 150 (10.1) | |
Clinical types, n (%) | ||||
Mild | 842 (29.4) | 637 (46.4) | 205 (13.8) | < 0.001 |
Moderate | 1585 (55.4) | 598 (43.6) | 987 (66.2) | |
Severe | 329 (11.5) | 95 (6.9) | 234 (15.7) | |
Critical | 106 (3.7) | 42 (3.1) | 64 (4.3) | |
White blood cells (109/L) | 7.10 ± 4.71 | 7.09 ± 5.20 | 7.11 ± 4.21 | 0.920 |
Red blood cells (1012/L) | 4.08 ± 0.85 | 4.12 ± 0.86 | 4.05 ± 0.84 | 0.033 |
Hemoglobin (g/L) | 120.18 ± 23.76 | 120.71 ± 23.79 | 119.69 ± 23.73 | 0.251 |
Platelets (109/L) | 225.84 ± 107.35 | 225.57 ± 108.12 | 226.09 ± 106.68 | 0.896 |
Neutrophil (109/L) | 5.31 ± 4.39 | 5.20 ± 4.89 | 5.41 ± 3.86 | 0.190 |
Lymphocyte (109/L) | 1.11 ± 0.91 | 1.17 ± 0.72 | 1.06 ± 1.05 | < 0.001 |
Monocyte (109/L) | 0.60 ± 0.63 | 0.64 ± 0.80 | 0.57 ± 0.41 | 0.009 |
Eosinophil (109/L) | 0.06 ± 0.11 | 0.07 ± 0.12 | 0.05 ± 0.10 | < 0.001 |
Basophil (109/L) | 0.02 ± 0.03 | 0.02 ± 0.03 | 0.01 ± 0.03 | < 0.001 |
Alanine aminotransferase (U/L) | 30.34 ± 81.87 | 29.58 ± 69.49 | 31.04 ± 91.83 | 0.629 |
Aspartate aminotransferase (U/L) | 43.30 ± 263.01 | 48.70 ± 361.29 | 38.32 ± 112.60 | 0.308 |
Glutamyl transpeptidase (U/L) | 44.63 ± 74.88 | 43.74 ± 75.19 | 45.45 ± 74.62 | 0.542 |
Alkaline phosphatase (U/L) | 82.56 ± 56.86 | 86.15 ± 66.99 | 79.25 ± 45.36 | 0.001 |
Cholinesterase (U/L) | 6090.21 ± 2077.49 | 6339.82 ± 2121.92 | 5860.38 ± 2009.19 | < 0.001 |
Total protein (g/L) | 62.52 ± 7.25 | 63.44 ± 7.29 | 61.68 ± 7.12 | < 0.001 |
Albumin (g/L) | 35.62 ± 5.52 | 36.76 ± 5.44 | 34.58 ± 5.38 | < 0.001 |
Globulin (g/L) | 26.89 ± 5.31 | 26.65 ± 5.65 | 27.10 ± 4.97 | 0.023 |
Total bilirubin (μmol/L) | 12.23 ± 17.39 | 13.24 ± 22.53 | 11.31 ± 10.56 | 0.004 |
Direct bilirubin (μmol/L) | 6.42 ± 13.74 | 7.02 ± 17.80 | 5.87 ± 8.40 | 0.029 |
Indirect bilirubin (μmol/L) | 5.99 ± 7.48 | 6.28 ± 6.35 | 5.71 ± 8.38 | 0.041 |
Total bile acid (μmol/L) | 7.46 ± 18.67 | 8.08 ± 21.51 | 6.88 ± 15.58 | 0.092 |
Prealbumin (mg/L) | 162.24 ± 79.59 | 177.45 ± 80.50 | 148.24 ± 76.12 | < 0.001 |
Alpha-fucosidase (U/L) | 23.21 ± 10.46 | 23.96 ± 10.99 | 22.51 ± 9.90 | < 0.001 |
Urea (mmol/L) | 7.56 ± 8.25 | 6.94 ± 6.13 | 8.14 ± 9.76 | < 0.001 |
Creatinine (μmol/L) | 133.96 ± 202.80 | 122.87 ± 178.85 | 144.17 ± 222.15 | 0.005 |
Glomerular filtration rate(ml/min*1.73 m2) | 100.00 ± 47.32 | 104.25 ± 47.97 | 96.09 ± 46.38 | < 0.001 |
Uric acid (μmol/L) | 306.71 ± 132.41 | 311.28 ± 129.76 | 302.51 ± 134.72 | 0.076 |
Total carbon dioxide (mmol/L) | 24.23 ± 11.37 | 24.48 ± 9.57 | 24.00 ± 12.81 | 0.252 |
Prothrombin time (s) | 12.00 ± 2.83 | 11.90 ± 1.99 | 12.09 ± 3.43 | 0.073 |
International standardization ratio | 1.20 ± 6.96 | 1.02 ± 0.18 | 1.36 ± 9.64 | 0.177 |
Fibrinogen (g/L) | 4.18 ± 2.62 | 3.79 ± 1.33 | 4.54 ± 3.35 | < 0.001 |
Activated partial thromboplastin time (s) | 29.74 ± 9.33 | 29.34 ± 6.43 | 30.11 ± 11.35 | 0.025 |
Thrombin time (s) | 16.41 ± 8.77 | 16.46 ± 8.80 | 16.36 ± 8.73 | 0.777 |
Antithrombin-III (%) | 83.92 ± 15.86 | 85.04 ± 16.81 | 82.90 ± 14.87 | < 0.001 |
Prothrombin activity (%) | 83.75 ± 15.49 | 84.48 ± 15.86 | 83.08 ± 15.12 | 0.016 |
D-dimer (mg/L) | 2.07 ± 5.50 | 2.06 ± 5.95 | 2.08 ± 5.04 | 0.929 |